Edelstein SL - Via the Restoring Insulin Secretion (RISE) Adult Medication Study and the RISE pediatric medication Study, the researchers sought to compare β-cell responses to pharmacological interventions among the two age-groups to improve or preserve β-cell function. Randomization of obese youth and adults with impaired glucose tolerance (IGT) or recently diagnosed type 2 diabetes to 3 months of insulin glargine followed by 9 months of metformin, or 12 months of metformin was done. Deterioration of β-cell function during treatment and after treatment withdrawal, with no differences between treatment groups in youth was observed while in adults, improvement in β-cell function during treatment was noted. A more adverse trajectory of β-cell deterioration in youth was supported by the difference in β-cell function outcomes in response to medications in youth vs adults.